IPILIMUMAB (YERVOY)

Course overview

Ipilimumab is approved by the U.S. FDA and the European Medicines Agency (EMA) to treat unresectable or metastatic malignant melanoma in adults. It requires close monitoring because of severe, potentially fatal immune-mediated adverse reactions. This continuing education module is designed to give the reader/learner an increased understanding of ipilimumab. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.